Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T20:13:18.470Z.
Calculation as of: 2026-10-06T20:13:18.470Z.
Quote observation: 2026-10-06T19:59:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79d0a2820bd4cbdc8dee1371cb6304dc007cf4c401fb8f8a9623f82368031b99
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$2.13M
EV/EBIT Ratio
N/A
TTM Avg
26760113783.26x
3Y Avg
32032508565.60x
5Y Avg
32032508565.60x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransCode Therapeutics, Inc. (RNAZ) | $1.92M | N/A | N/A | N/A | N/A |
| Autonomix Medical, Inc. (AMIX)vs › | $1.88M | N/A | N/A | N/A | N/A |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | N/A | N/A | N/A | N/A |
| Beyond Air, Inc. (XAIR)vs › | $1.84M | N/A | N/A | N/A | N/A |
| Profusa, Inc. Common Stock (PFSA)vs › | $1.83M | N/A | N/A | N/A | N/A |
| Alaunos Therapeutics, Inc. (TCRT)vs › | $1.81M | N/A | N/A | N/A | N/A |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | N/A | 26760113783.26x | 32032508565.60x | 32032508565.60x |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.14M | N/A | N/A | N/A | N/A |
| Silo Pharma, Inc. (SILO)vs › | $1.64M | N/A | N/A | N/A | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
